Sophia Antipolis – 25 April 2021
: There are no screening programmes for atrial fibrillation in Europe, according to a study presented at EHRA 2021, an online scientific congress of the European Society of Cardiology (ESC).
1
Atrial fibrillation is the most common heart rhythm disorder, affecting more than 40 million individuals globally.
2 People with the disorder have a five times greater risk of stroke. Symptoms of atrial fibrillation include palpitations, fatigue, and chest pain.
Interviews with regulators and leading healthcare professionals, conducted by the European Heart Rhythm Association (EHRA) of the ESC, lay the groundwork for
AFFECT-EU, a large-scale EU funded project to detect atrial fibrillation and prevent subsequent strokes and death.
Bimekizumab Tops Secukinumab for Adult Plaque Psoriasis medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
email article
Simultaneous inhibition of interleukin(IL)-17A and 17F with bimekizumab led to more rapid clearance of plaque psoriasis in significantly more patients as compared with the IL-17A inhibitor secukinumab (Cosentyx), a large randomized trial showed.
After 16 weeks, 61.7% of patients treated with bimekizumab had a 100% reduction in the Psoriasis Area and Severity Index (PASI 100) compared with 48.9% of the secukinumab arm. The 12.7% absolute difference met statistical criteria for noninferiority and superiority in favor of bimekizumab. Clearance occurred more rapidly with bimekizumab, as 71.0% of patients randomized to the IL-17A/F inhibitor had 75% or greater reduction from baseline in the PASI score at 4 weeks compared with 47.3% of the secukinumab arm.
(BioEnergy International) RepCAT, a new process by BCI-BioEnergy Internationa, Austrian plant manufacturer and technology provider, has been approved BDI’s RepCAT technology approved for safe disposal of high-risk fat material.
World’s first biodiesel production process to use a recyclable catalyst. Using this technology, 3 plants are currently being built.
Already for decades, BDI-BioEnergy International has been committed to the development of innovative technologies. The company has been able to create technological milestones, above all, in biodiesel production from residual and waste materials. For example, the company built the world’s first plants using waste cooking oils, animal waste fats or grease trap fats to produce biodiesel.
European Food Safety Agency greenlights BDI-Bioenergy s RepCAT for high risk fat materials : Biofuels Digest biofuelsdigest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biofuelsdigest.com Daily Mail and Mail on Sunday newspapers.